Vicore Pharma Holding AB ADS

VCRE

시가총액 US$2.53억

STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcare Conference. Location: Lotte New York Palace, New York Format: Panel discussion and 1×1 meetings Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation Date and time: Tuesday, October 20, 2026, 2:00-2:30 PM ET Participant: Ahmed Mousa, CEO Webcast: Link For further information, please contact: Hans Jeppsson, CFO, +46 (0)70 553 14 65, [email protected] About Vicore Pharma Holding AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to participants in the incentive programs Board LTIP 2023, Board LTIP 2024 and Board RSU 2025. The shares were issued through the exercise of 117,737 share awards, which are entitled to 118,916 shares.

STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum. Location: Virtual Format: Presentation and 1×1 meetings Presentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ET Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO; and Bernt van den Blink, CMO Webcast: Link For more information, please contact: Hans Jeppsson, CFO, +46 70 553 14 65, [email protected] About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences: Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, Mass.Format: 1×1 meetingsParticipation Date: Tuesday, September 8, 2026Participant: Ahmed Mousa, Chief Executive Officer Cantor Global Healthcare Conference Location: Waldorf Astoria New York, New York, N.Y.Format: Fireside chat and 1×1 meetingsFireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ETWebcast: Link Participant: Ahmed Mousa, Chief Executive Officer For more information, please contact: Hans Jeppsson, CFO, +46 70 553 14 65, [email protected] About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the European Respiratory Society (ERS) Congress 2026, taking place in Barcelona, Spain and online September 5-9, 2026. Vicore will present new data on the design and baseline characteristics of patients enrolled in the global Phase 2b ASPIRE trial in buloxibutid, the company's lead program in idiopathic pulmonary fibrosis (IPF), along with translational findings on AT2 receptor activation in alveolar epithelial type II cells and its association with MMP-13, a collagenase linked to fibrosis resolution.

STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum. Location: Boston Harbor Hotel, Boston, Mass.